New hope for tough lung cancers: experimental combo targets telomeres to restore immunotherapy response
Disease control
Recruiting now
This phase 3 study tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer whose disease has worsened after two prior treatments. About 300 adults will be randomly assigned to receive either the THI…
Phase: PHASE3 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated May 11, 2026 20:38 UTC